Apac
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    DevOps

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    IT Services

    Marine Tech

    Networking

    PropTech

    Remote Work

    Robotics

    Scheduling Software

    Sensor Tech

    Simulation

    Smart City

    Software Testing

    Startup

    Storage

    Unified Communication

    Web Development

    Wireless

  • Automotive

    Banking

    Capital Market

    Construction

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Gov and Public

    Healthcare

    Insurance

    Legal

    Logistics

    Manufacturing

    Media and Entertainment

    Metals and Mining

    Pharma and Life Science

    Retail

    Sports

    Travel and Hospitality

  • CISCO

    Google

    IBM

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Collaboration

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Digital Signage

    Enterprise Architecture

    Enterprise Asset Management

    Enterprise Communications

    Enterprise Contract Management

    Enterprise Performance Management

    ERP

    Facility Management

    Field Service

    Fleet Management

    Gamification

    HR Technology

    IT Infrastructure

    IT Service Management

    Managed Services

    PLM

    Procurement

    Product Management

    Project Management

    RegTech

    Revenue Management

    Sales Tech

Menu
    • CISCO
    • Collaboration
    • Compliance
    • Contact Center
    • Healthcare
    • IT Service Management
    • Microsoft
    • Retail
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Healthcare
    Editor's Pick (1 - 4 of 8)
    left
    Technology’s Role in The Care and Quality of Life for The Aged

    Jose A Perez, Chief Information Officer, Hammondcare

    Digital Transformation - The Right Way

    Amit Goel, CIO, Metropolis Healthcare

    The (E-) Doctor Is In: What Trends to Spot in Healthcare Technology Today

    Dickon Smart-Gill, CIO, Bumrungrad International Hospital

    Analytics and AI in Healthcare

    Steven Parrish, CIO, Taranaki District Health Board

    Document Management in the Cloud

    Alex Choy, EVP R&D CIO, Change Healthcare

    China Embracing Connected Health

    Geoff Feakes, Group CIO, Tunstall Healthcare

    How Healthy is Your IT?

    John Sutherland-CIO-Ramsay Health Care

    Enterprise Architecture - An Extremely Valuable Discipline for Great Businesses

    Ken Spangler, SVP & CIO FedEx Ground and FedEx Freight, FedEx Services IT

    right

    Yantai-based Biopharmaceutical Company RemeGen Raises $100m in a Private Financing Round

    By Apac CIO Outlook | Monday, April 20, 2020
    Tweet

    RemeGen, which presently has one new drug application filed in China, intends to use the newly raised capital to proceed with the development of its early-stage drug discovery platform, to widen its manufacturing facilities, and to advance the commercialization efforts of its two lead molecules, RC18 (telitacicept) and RC48

    Fremont, CA: RemeGen, a Yantai, China-based biopharmaceutical company, has raised approximately $100m in a private financing round co-led by Lilly Asia Ventures and Lake Bleu Capital with participation from Hudson Bay Capital, Vivo Capital, OrbiMed, Janchor Partners, and other existing investors. Loyal Valley Capital and China Reform Conson Soochow Overseas Fund have also invested in the funding round.

    "It is a great honor to receive the recognition and support from the top investment institutions in the biomedical space," said Jianmin Fang, Ph.D., founder and CEO of RemeGen. "Reaching this funding milestone will allow us to pursue further our vision of developing biologics of the future. Through research, development, manufacturing, and commercialization of novel biologics – most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs) – RemeGen aims to fulfill the unmet medical needs of patients everywhere facing conditions such as autoimmune diseases and cancer, bringing us one step closer to the future of medicine."

    Top 20 Healthcare Technology Solution Companies - 2019"We are honored to lead this round of funding," says Dr. Fei Chen, Managing Partner of Lilly Asia Ventures. "As a long-term investor, we look forward to partnering with RemeGen to become a leading global biopharmaceutical. We believe that the biologic drugs innovated by RemeGen will continue to benefit patients at home and abroad."

    RemeGen was founded in 2008 under the leadership of Jianmin Fang, Ph.D., CEO, and is a biopharmaceutical firm with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs. The firm focuses on researching and developing innovative biologics in the therapeutic areas of autoimmune diseases, cancer, and ophthalmology. In a short period, RemeGen has built a prolific pipeline of over ten innovative molecules with two molecules, spanning five disease indications in Phase III or pivotal trials in China.

    RemeGen, which presently has one new drug application filed in China, intends to use the newly raised capital to proceed with the development of its early-stage drug discovery platform, to widen its manufacturing facilities, and to advance the commercialization efforts of its two lead molecules, RC18 (telitacicept) and RC48. Telitacicept is a fusion protein with a new drug application filed in China for systemic lupus erythematosus (SLE). It is also currently in Phase II or Phase III trials for six other autoimmune disease indications. RC48, a HER2 ADC for the treatment of various solid tumors, is now in pivotal clinical trials for gastric and urothelial cancers.

    See also: Top Biotech Startups

    tag

    Startups

    Weekly Brief

    loading
    Top 10 Big Data Solution Companies - 2020
    Top 10 Big Data Consulting/ Service Companies - 2020

    Featured Vendors

    Kogentix

    Boyd Davis, CEO

    Illation

    Dallas Newton, Country Business Manager

    ON THE DECK

    Big Data 2020

    Top Vendors

    Big Data 2019

    Top Vendors

    Big Data 2019

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    Four Security Issues in IoT

    Four Security Issues in IoT

    Four Use Cases of AR/VR Technology in Employee Training

    Four Use Cases of AR/VR Technology in Employee Training

    Five Major Trends in Digital Transformation for Businesses

    Five Major Trends in Digital Transformation for Businesses

    How Blockchain Reinvents Regtech

    How Blockchain Reinvents Regtech

    Five AI Technologies to Help Boost Business

    Five AI Technologies to Help Boost Business

    Popular E-Commerce Growth Trends in 2021

    Popular E-Commerce Growth Trends in 2021

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy  |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/-yantaibased-biopharmaceutical-company-remegen-raises-100m-in-a-private-financing-round--nwid-7435.html